Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver & Lung Disorder

Regeneron Pharmaceuticals will share in development of Tessera Therapeutics’ TSRA-196, a Phase 1-ready gene-editing therapy for alpha-1 antitrypsin deficiency (AATD). Other companies developing genetic medicines for this rare disease include Beam Therapeutics, Wave Life Sciences, Korro Bio, and AIRNA. The post Regeneron Puts Up $150M to Partner on Tessera Gene-Editing Med for Rare Liver &…

Read More

Global COVID-19 Tracker

This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

Read More

What Is Needed to Rebuild Trust in U.S. Healthcare?

Americans largely trust their doctors but are skeptical of payers, drugmakers and hospital leadership — a divide fueled by rising costs and a complex, opaque healthcare system. Kristin Wikelius of United States of Care said restoring confidence will require more transparency, simpler navigation and policies that prioritize preventive care. The post What Is Needed to…

Read More

For Merck, AI Puts Humans In the “Right Room”

The healthcare industry is contending with a difficult question: how to properly wield AI without taking on too much risk? Inherent in this battle is the role of humans. Here’s how Merck’s chief data officer is viewing AI. The post For Merck, AI Puts Humans In the “Right Room” appeared first on MedCity News.

Read More